期刊
CELLS
卷 8, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/cells8101160
关键词
cell- and tissue-based therapy; mesenchymal stem cells; thrombosis; anticoagulants
类别
资金
- Fondation Saint-Luc (mandat de recherche temps plein)
- Fonds National de la Recherche Scientifique et Medicale (FNRS, Belgium)
- FRIA fellowship [F 3/5/5 - FRIA/FC]
Mesenchymal stem cells (MSCs) are currently studied and used in numerous clinical trials. Nevertheless, some concerns have been raised regarding the safety of these infusions and the thrombogenic risk they induce. MSCs express procoagulant activity (PCA) linked to the expression of tissue factor (TF) that, when in contact with blood, initiates coagulation. Some even describe a dual activation of both the coagulation and the complement pathway, called Instant Blood-Mediated Inflammatory Reaction (IBMIR), explaining the disappointing results and low engraftment rates in clinical trials. However, nowadays, different approaches to modulate the PCA of MSCs and thus control the thrombogenic risk after cell infusion are being studied. This review summarizes both in vitro and in vivo studies on the PCA of MSC of various origins. It further emphasizes the crucial role of TF linked to the PCA of MSCs. Furthermore, optimization of MSC therapy protocols using different methods to control the PCA of MSCs are described.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据